In the phase I component of the LIBRETTO-001 trial investigating LOXO-292, an ATP-competitive highly selective small molecule RET inhibitor (23), LOXO-292 showed robust antitumor activity in patients with RET fusion-positive PTC and NSCLC, and RET mutation-positive medullary thyroid cancer. Here, RET is linked to medullary thyroid gland carcinoma.